The development of second-generation forskolin analogs, namely -6-deox
y-7-deacetyl-7-methylaminocarbonylforskolin (HIL 568) as a potential a
ntiglaucoma agent, 6-(3-dimethyl-aminopropionyl)forskolin hydrochlorid
e (NKH 477) as a potential cardiotonic agent and a standardised Makand
i (Coleus forskohlii)-based phytotherapeutic product as a potential an
tithrombotic agent is described.